Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Insulin Resistance 5 Hyperglycemia 3 Polycystic Ovary Syndrome 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Oligomenorrhea 1 Neoplasms 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Intracranial Aneurysm 1 Hypoglycemia 1 Hyperphagia 1 Hyperinsulinism 1 Hyperandrogenism 1 Hirsutism 1 Diabetes Mellitus, Type 2 1 Diabetes Mellitus, Type 1 1 Congenital Abnormalities 1 Colorectal Neoplasms 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

Gemcitabine 685 130-nm albumin-bound paclitaxel 199 Fluorouracil 190 Oxaliplatin 177 Albumin-Bound Paclitaxel 154 Capecitabine 137 Leucovorin 133 Irinotecan 114 Radiotherapy 96 Taxes 85 pembrolizumab 81 Cisplatin 73 Erlotinib Hydrochloride 70 Radiosurgery 69 Nivolumab 56 Drug Therapy 56 Bevacizumab 54 Magnetic Resonance Spectroscopy 51 Cyclophosphamide 50 folfirinox 45 Specimen Handling 43 Docetaxel 42 Cetuximab 40 Biopsy 39 irinotecan sucrosofate 38 S 1 (combination) 36 Pancreaticoduodenectomy 35 Blood Specimen Collection 34 Surgical Procedures, Operative 31 Paclitaxel 30

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Pancreatic Neoplasms × Insulin × Clear all

NCT05663515 2026-06-02

EXCEED

AstraZeneca

24,000 enrolled

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡